ArticleCurrent cancer drug targets2026
Anti-breast Cancer Potential of
Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProsopis cineraria L. (PCL) is a herbal plant commonly used in Asia for the therapeutic intervention of different kinds of illnesses. Preclinical reports have revealed the beneficial effects of PCL against various types of life-threatening diseases, including cancer. However, studies targeting breast cancer (BCa) and bioactive for its mechanistic approach are limited or not available.
methodsThe current work utilized network pharmacology, built a network between plant compounds and BCa targets, and explored the effective phytocompounds of PCL and its possible mode of action. All phytoconstituents of PCL were segregated using the IMPPAT database, and thus, potential phytoconstituents were selected for this study. Phytocompounds and BCa target data were entered into Cytoscape software to compose the PCL network, and subsequently GO and pathway enrichment analysis were examined. Molecular docking and in vitro experiments were used to further validate the network pharmacology results.
resultsWe retrieved 24 phytocompounds from PCL and 301 potent BCa-associated targets for network construction, and obtained one main ingredient, luteolin of PCL. MMP9, GSK3Β, PARP1, CYP19A1, MMP2, ABCG2, ESR2, HMGCR, AR, and ABCB1 have been recognized as crucial targets of PCL in BCa treatment. Subsequent in vitro experiments showed that PCL and its final screened constituent, luteolin, inhibited the proliferation of MDA-MB-231 cells and reduced the expression level of MMP9 target genes.
conclusionNetwork analysis exhibited that PCL exerted a significant repressive impact on BCa by acting on tumor-associated signaling cascade, which would be helpful for future anticancer research of PCL against breast cancer.
Indexed as
Identifiers
42897900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.